Coronary artery disease (CAD) is the most common form of heart disease in Europe and the US. It is caused by a narrowing of the arteries due to deposits of fat and cholesterol, preventing enough blood reaching the heart. Symptoms include chest pain, shortness of breath and numbness in the arms and shoulders, and the disease can lead to heart attack.
However, whilst scientists know that high fat and high cholesterol diets play a significant role in the disease, they do not understand fully what makes some people more susceptible to the disease than others. They believe that many factors contribute, both environmental and genetic.
"Coronary artery disease is a major health issue in the Western world and we want to get to the root of what causes it," says Professor Dominique Gauguier from the Wellcome Trust Centre for Human Genetics at the University of Oxford. "It is a complex disease, so it's impossible to say 'We've found the gene for CAD'. Rather, it is caused by a number of factors, including the interaction of genes with other genes and with the environment."
Professor Gauguier, a Wellcome Trust Senior Research Fellow, is leading an international consortium, known as Functional Genomic Diagnostic Tools for Coronary Artery Disease (FGENTCARD). The project, which has received €3 million over 3 years from the European Commission, involves academic and industrial scientists from the UK, France, Denmark and Lebanon.
The consortium will use the latest technologies for analysing DNA to identify those at risk from CAD. These include functional genomics, taking a sequence of the genome and analysing the function of individual genes and their interaction with other genes to understand the role they play in disease.
Amongst other things, the study will look at the extent to which CAD risk factors, such as insulin resistance, hypertension and obesity, can be predicted using biomarkers in the blood. Scientists have already identified biomarkers which, when found in elevated levels, indicate the presence of certain types of tumour.
In addition, Professor Gauguier hopes that the study will offer an insight into tackling other complex diseases, through therapeutic and strategic means.
"We believe the study will play a key role in identifying targets for novel therapies to tackle the disease," says Professor Gauguier. "Ultimately, we hope that the wealth of information obtained by the project and the techniques that it helps us develop will lead to significant advances for disease diagnosis and prevention."
FGENTCARD builds on previous Wellcome Trust-funded research including BAIR, the Biological Atlas of Insulin Resistance, and CFG, the Cardiovascular Functional Genomics consortium.
Craig Brierley | alfa
Speed data for the brain’s navigation system
06.12.2016 | Deutsches Zentrum für Neurodegenerative Erkrankungen e.V. (DZNE)
Study suggests possible new target for treating and preventing Alzheimer's
02.12.2016 | Oregon Health & Science University
Have you ever wondered how you see the world? Vision is about photons of light, which are packets of energy, interacting with the atoms or molecules in what...
A multi-institutional research collaboration has created a novel approach for fabricating three-dimensional micro-optics through the shape-defined formation of porous silicon (PSi), with broad impacts in integrated optoelectronics, imaging, and photovoltaics.
Working with colleagues at Stanford and The Dow Chemical Company, researchers at the University of Illinois at Urbana-Champaign fabricated 3-D birefringent...
In experiments with magnetic atoms conducted at extremely low temperatures, scientists have demonstrated a unique phase of matter: The atoms form a new type of quantum liquid or quantum droplet state. These so called quantum droplets may preserve their form in absence of external confinement because of quantum effects. The joint team of experimental physicists from Innsbruck and theoretical physicists from Hannover report on their findings in the journal Physical Review X.
“Our Quantum droplets are in the gas phase but they still drop like a rock,” explains experimental physicist Francesca Ferlaino when talking about the...
The Max Planck Institute for Physics (MPP) is opening up a new research field. A workshop from November 21 - 22, 2016 will mark the start of activities for an innovative axion experiment. Axions are still only purely hypothetical particles. Their detection could solve two fundamental problems in particle physics: What dark matter consists of and why it has not yet been possible to directly observe a CP violation for the strong interaction.
The “MADMAX” project is the MPP’s commitment to axion research. Axions are so far only a theoretical prediction and are difficult to detect: on the one hand,...
Broadband rotational spectroscopy unravels structural reshaping of isolated molecules in the gas phase to accommodate water
In two recent publications in the Journal of Chemical Physics and in the Journal of Physical Chemistry Letters, researchers around Melanie Schnell from the Max...
16.11.2016 | Event News
01.11.2016 | Event News
14.10.2016 | Event News
06.12.2016 | Health and Medicine
06.12.2016 | Life Sciences
05.12.2016 | Power and Electrical Engineering